Avalo Therapeutics, Inc. - AVTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Caligan Partners LP | 5.9% | 3,163,866 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | David Johnson | 5.9% | 3,163,866 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | RA Capital Management, L.P. | 6.3% | 3,483,099 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Peter Kolchinsky | 6.3% | 3,483,099 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Rajeev Shah | 6.3% | 3,483,099 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | RA Capital Healthcare Fund, L.P. | 6.3% | 3,483,099 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Nantahala Capital Management, LLC | 3.54% | 1,862,250 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Wilmot B. Harkey | 3.54% | 1,862,250 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Daniel Mack | 3.54% | 1,862,250 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 2.8% | 1,466,153 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 2.8% | 1,466,153 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.1% | 1,107,854 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 2.1% | 1,107,854 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.4% | 185,010 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.4% | 185,010 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 4.8% | 2,574,007 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 5.3% | 2,801,545 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BVF INC/IL | 5.3% | 2,801,545 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 5.3% | 2,801,545 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | T. Rowe Price Investment Management, Inc. | 0.0% | 3,670 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Avoro Capital Advisors LLC | 4.44% | 2,333,333 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Behzad Aghazadeh | 4.44% | 2,333,333 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 6.87% | 3,610,000 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 6.87% | 3,610,000 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | David Kroin | 6.87% | 3,610,000 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 5.5% | 2,900,000 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Michael Cho | 5.5% | 2,900,000 | View |
| Aug 07, 2026 | SCHEDULE 13G/A | FMR LLC | 10.8% | 5,737,966 | View |
| Aug 07, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 10.8% | 5,737,966 | View |
| Aug 06, 2026 | SCHEDULE 13G/A | FMR LLC | 9.7% | 5,100,216 | View |
| Aug 06, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 9.7% | 5,100,216 | View |
| Jul 27, 2026 | SCHEDULE 13G | BlackRock, Inc. | 6.5% | 3,415,731 | View |
| Jul 06, 2026 | SCHEDULE 13G/A | Millennium Management LLC | 0.0% | 9,857 | View |
| Jul 06, 2026 | SCHEDULE 13G/A | Millennium Group Management LLC | 0.0% | 9,857 | View |
| Jul 06, 2026 | SCHEDULE 13G/A | Israel A. Englander | 0.0% | 9,857 | View |
| Jun 18, 2026 | SCHEDULE 13G | Commodore Capital LP | 9.9% | 5,721,109 | View |
| Jun 18, 2026 | SCHEDULE 13G | Commodore Capital Master LP | 9.9% | 5,721,109 | View |
| Jun 18, 2026 | SCHEDULE 13G | Robert Egen Atkinson | 9.9% | 5,721,109 | View |
| Jun 18, 2026 | SCHEDULE 13G | Michael Kramarz | 9.9% | 5,721,109 | View |
| Jun 05, 2026 | SCHEDULE 13G/A | FMR LLC | 6.1% | 3,188,401 | View |
| Jun 05, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 6.1% | 3,188,401 | View |
| May 29, 2026 | SCHEDULE 13G | Deep Track Capital, LP | 5.81% | 3,055,027 | View |
| May 29, 2026 | SCHEDULE 13G | Deep Track Biotechnology Master Fund, Ltd. | 5.81% | 3,055,027 | View |
| May 29, 2026 | SCHEDULE 13G | David Kroin | 5.81% | 3,055,027 | View |
| May 26, 2026 | SCHEDULE 13G | Point72 Asset Management, L.P. | 5.2% | 2,710,817 | View |
| May 26, 2026 | SCHEDULE 13G | Point72 Capital Advisors, Inc. | 5.2% | 2,710,817 | View |
| May 26, 2026 | SCHEDULE 13G | Steven A. Cohen | 5.2% | 2,710,817 | View |
| May 15, 2026 | SCHEDULE 13G/A | Logos Global Management LP | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Logos Global Management GP LLC | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Logos Global Master Fund LP | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Logos GP LLC | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Arsani William | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | RA Capital Management, L.P. | 9.9% | 2,455,655 | View |
| May 15, 2026 | SCHEDULE 13G/A | Peter Kolchinsky | 9.9% | 2,455,655 | View |
| May 15, 2026 | SCHEDULE 13G/A | Rajeev Shah | 9.9% | 2,455,655 | View |
| May 15, 2026 | SCHEDULE 13G/A | RA Capital Healthcare Fund, L.P. | 9.9% | 2,455,655 | View |
| May 15, 2026 | SCHEDULE 13G/A | OrbiMed Advisors LLC | 2.1% | 475,165 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.4% | 1,258,371 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 5.4% | 1,258,371 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 4.0% | 919,912 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 4.0% | 919,912 | View |
| May 15, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.6% | 141,562 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.6% | 141,562 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.3% | 2,178,283 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 2,347,845 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 2,347,845 | View |
| May 15, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 2,347,845 | View |
| May 15, 2026 | SCHEDULE 13G/A | Caligan Partners LP | 7.2% | 1,635,023 | View |
| May 15, 2026 | SCHEDULE 13G/A | David Johnson | 7.2% | 1,635,023 | View |
| May 15, 2026 | SCHEDULE 13G | T. Rowe Price Investment Management, Inc. | 9.5% | 2,162,684 | View |
| May 15, 2026 | SCHEDULE 13G | Avoro Capital Advisors LLC | 5.75% | 1,410,000 | View |
| May 15, 2026 | SCHEDULE 13G | Behzad Aghazadeh | 5.75% | 1,410,000 | View |
| May 14, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 5.5% | 1,340,840 | View |
| May 14, 2026 | SCHEDULE 13G/A | Michael Cho | 5.5% | 1,340,840 | View |
| May 12, 2026 | SCHEDULE 13G | TCG Crossover GP II, LLC | 7.9% | 3,017,120 | View |
| May 12, 2026 | SCHEDULE 13G | TCG Crossover Fund II, L.P. | 7.9% | 3,017,120 | View |
| May 12, 2026 | SCHEDULE 13G | Chen Yu | 7.9% | 3,017,120 | View |
| May 06, 2026 | SCHEDULE 13G/A | FMR LLC | 12.6% | 2,879,481 | View |
| May 06, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 12.6% | 2,879,481 | View |
| Apr 01, 2026 | SCHEDULE 13G | Logos Global Management LP | 5.6% | 1,285,000 | View |
| Apr 01, 2026 | SCHEDULE 13G | Logos Global Management GP LLC | 5.6% | 1,285,000 | View |
| Apr 01, 2026 | SCHEDULE 13G | Logos Global Master Fund LP | 5.6% | 1,285,000 | View |
| Apr 01, 2026 | SCHEDULE 13G | Logos GP LLC | 5.6% | 1,285,000 | View |
| Apr 01, 2026 | SCHEDULE 13G | Arsani William | 5.6% | 1,285,000 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.